OncoMatch/Clinical Trials/NCT05498792
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
Is NCT05498792 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including CBL0137 and Ipilimumab for locally advanced or metastatic melanoma.
Treatment: CBL0137 · Ipilimumab · Nivolumab — Phase I, open label, dose-escalation, and safety study designed to assess the safety and biologic activity of the investigational agent CBL0137 in combination with standard of care drugs, ipilimumab and nivolumab in sequential cohorts of adult patients with locally advanced and metastatic melanoma who are candidates for immune checkpoint blockade and have tumors accessible for serial biopsies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: CTLA-4 or PD1/PD-L1 pathway targeted systemic treatment
Prior treatment with CTLA-4 or PD1/PD-L1 pathway targeted systemic treatment
Lab requirements
Blood counts
normal organ and marrow function
Kidney function
normal organ and marrow function
Liver function
normal organ and marrow function
Patients must have normal organ and marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fox Chase Cancer Center · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify